🇺🇸 FDA
Patent

US 6878709

3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists

expired A61PA61P1/02A61P1/04

Quick answer

US patent 6878709 (3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists) held by Pharmacopeia Drug Discovery, Inc. expires Mon Apr 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Pharmacopeia Drug Discovery, Inc.
Grant date
Tue Apr 12 2005 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61P, A61P1/02, A61P1/04, A61P11/00, A61P11/06